Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017–2018

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-06-19 DOI:10.1080/21645515.2024.2354013

Kailey Hughes Kramer, Richard K. Zimmerman, Catherine L. Haggerty, G. K. Balasubramani, Mary Patricia Nowalk, Emily T. Martin, Manjusha Gaglani, C. Hallie Phillips, Edward Belongia, Jessie Chung, Fernanda P. Silveira

引用次数: 0

Abstract

While the number of immunocompromised (IC) individuals continues to rise, the existing literature on influenza vaccine effectiveness (VE) in IC populations is limited. Understanding the vaccine eff...

查看原文本刊更多论文

2017-2018 年流感疫苗对预防门诊免疫力低下成人实验室确诊流感感染的有效性

虽然免疫力低下（IC）人群的数量在不断增加，但现有文献中有关IC人群流感疫苗有效性（VE）的研究却很有限。了解流感疫苗在IC人群中的有效性...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.